Related Experiment Video
Updated: Dec 22, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
5.1K
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang1, Wentao Li1, Dubravka Drabek2,3
1Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Nature Communications
|May 6, 2020
Summary
A new human monoclonal antibody effectively neutralizes SARS-CoV-2, the virus causing COVID-19, in laboratory tests. This cross-neutralizing antibody may offer a potential strategy for preventing and treating COVID-19 and similar coronaviruses.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- The novel coronavirus SARS-CoV-2 has caused a global COVID-19 pandemic.
- Effective vaccines and targeted therapeutics for COVID-19 are currently unavailable.
Purpose of the Study:
- To identify and characterize a human monoclonal antibody with neutralizing activity against SARS-CoV-2.
- To investigate the antibody's potential for cross-neutralization against related coronaviruses.
Main Methods:
- Development and testing of a human monoclonal antibody.
- In vitro cell culture assays to assess viral neutralization.
- Epitope mapping to identify the target site on the virus.
Main Results:
- A human monoclonal antibody demonstrated potent neutralization of SARS-CoV-2 in cell culture.
- The antibody also showed cross-neutralizing activity against SARS-CoV.
- The antibody targets a conserved epitope shared by both SARS-CoV-2 and SARS-CoV.
Conclusions:
- A cross-neutralizing human monoclonal antibody has been identified.
- This antibody shows promise for the prevention and treatment of COVID-19.
- Targeting communal epitopes may be a viable strategy for broad coronavirus therapeutic development.
